Decensi A - Search Results

1

Effect of fenretinide on ovarian carcinoma occurrence.

De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B, Decensi A, Veronesi U. De Palo G, et al. Among authors: decensi a. Gynecol Oncol. 2002 Jul;86(1):24-7. doi: 10.1006/gyno.2002.6663. Gynecol Oncol. 2002. PMID: 12079295 Clinical Trial.

2

Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint.

Decensi A, Bruno S, Giaretti W, Torrisi R, Curotto A, Gatteschi B, Geido E, Polizzi A, Costantini M, Bruzzi P, et al. Decensi A, et al. J Cell Biochem Suppl. 1992;16I:139-47. doi: 10.1002/jcb.240501327. J Cell Biochem Suppl. 1992. PMID: 1305678 Clinical Trial.

3

Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.

Boccardo F, Decensi AU, Guarneri D, Martorana G, Fioretto L, Mini E, Macaluso MP, Giuliani L, Santi L, Periti P. Boccardo F, et al. Among authors: decensi au. Cancer Detect Prev. 1991;15(6):501-3. Cancer Detect Prev. 1991. PMID: 1782640 Clinical Trial.

4

Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).

Boccardo F, Decensi A, Guarneri D, Rubagotti A, Oneto F, Martorana G, Giuliani L, Delli Ponti U, Petracco S, Cortellini P, et al. Boccardo F, et al. Among authors: decensi a. Eur Urol. 1990;18 Suppl 3:48-53. doi: 10.1159/000463981. Eur Urol. 1990. PMID: 2151277 Clinical Trial.

5

Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.

Boccardo F, Canobbio L, Resasco M, Decensi AU, Pastorino G, Brema F. Boccardo F, et al. Among authors: decensi au. J Cancer Res Clin Oncol. 1990;116(5):503-6. doi: 10.1007/BF01613002. J Cancer Res Clin Oncol. 1990. PMID: 2229142 Clinical Trial.

6

DNA flow cytometry as a surrogate end-point in patients with superficial bladder cancer treated with 4-HPR.

Decensi A, Curotto A, Bruno S, Costantini M, Torrisi R, Gatteschi B, Cussotto M, Pizzorno R, Quattrini S, Repetto U, et al. Decensi A, et al. Eur J Cancer Prev. 1994 Jul;3(4):377-9. doi: 10.1097/00008469-199407000-00017. Eur J Cancer Prev. 1994. PMID: 7950899 Clinical Trial. No abstract available.

7

Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.

Torrisi R, Parodi S, Fontana V, Rondanina G, Formelli F, Costa A, Boccardo F, Decensi A. Torrisi R, et al. Among authors: decensi a. Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):507-10. Cancer Epidemiol Biomarkers Prev. 1994. PMID: 8000302

8

Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.

Decensi A, Formelli F, Torrisi R, Costa A. Decensi A, et al. J Cell Biochem Suppl. 1993;17G:226-33. doi: 10.1002/jcb.240531142. J Cell Biochem Suppl. 1993. PMID: 8007703 Clinical Trial.

9

Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.

Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U. Costa A, et al. Among authors: decensi a. Cancer Res. 1994 Apr 1;54(7 Suppl):2032s-2037s. Cancer Res. 1994. PMID: 8137334 Review.

10

Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.

Boccardo F, Cannata D, Rubagotti A, Guarneri D, Decensi A, Canobbio L, Curotto A, Martorana G, Pegoraro C, Selvaggi F, et al. Boccardo F, et al. Among authors: decensi a. J Clin Oncol. 1994 Jan;12(1):7-13. doi: 10.1200/JCO.1994.12.1.7. J Clin Oncol. 1994. PMID: 8270987 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results